How much does an individual pay out-of-pocket after medical insurance reimburses Eltrombopag?

Eltrombopag is an oral thrombopoietin receptor agonist, mainly used to treat chronic immune thrombocytopenia (ITP), hepatitis C-related thrombocytopenia, severe aplastic anemia and other diseases. The drug has been officially launched in China and has been included in the national medical insurance directory, which has greatly eased the financial burden on patients. According to the medical insurance policies of different provinces and cities, the reimbursement ratio is usually between 70% and 90%, so the personal out-of-pocket portion after medical insurance is relatively low.

The current selling price of Eltrombopag in China ranges from one to two thousand yuan to four to five thousand yuan. The specific price is related to the specifications, brand and purchasing channels. If a box is sold for about 4,000yuan, and medical insurance reimburses 80% for example, the patient only has to bear a cost of about 800yuan. Medical insurance policies vary slightly in different regions. It is recommended that patients consult the local hospital pharmacy or medical insurance bureau for detailed consultation before purchasing medicines to obtain accurate reimbursement amounts and procedures.

In addition to the original version of the drug reimbursed by domestic medical insurance, there are also multiple more affordable versions of generic drugs on the market, including generic versions of eltrombopag produced in Laos, India and Bangladesh. The ingredients of these generic drugs are basically the same as those of the original drugs, and their quality is relatively stable. Among them, the price of the Indian generic version is only a few hundred yuan per box, which is suitable for patients who cannot enjoy medical insurance or need to take medicine for a long time and are under great financial pressure. However, when choosing overseas generic drugs, you must purchase them through formal channels to ensure the quality and safety of the drugs.

Overall, the inclusion of eltrombopag in medical insurance has significantly reduced patients’ medication costs, which is especially significant for patients with chronic diseases who require long-term treatment. For patients with more limited financial resources, generic drugs also provide a viable alternative. No matter which version you choose, you should use the medication regularly under the guidance of a doctor, and regularly monitor platelet levels based on your condition to ensure the safety and effectiveness of the treatment.

Reference materials:https://go.drugbank.com/drugs/DB06210